Emergent BioSolutions (NYSE:EBS) Earns Buy Rating from Analysts at HC Wainwright

Equities research analysts at HC Wainwright began coverage on shares of Emergent BioSolutions (NYSE:EBS - Get Free Report) in a research note issued to investors on Monday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $15.00 price target on the biopharmaceutical company's stock. HC Wainwright's price target points to a potential upside of 62.16% from the stock's current price.

A number of other equities research analysts have also issued reports on EBS. Benchmark boosted their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Rodman & Renshaw restated a "buy" rating and set a $16.00 price objective on shares of Emergent BioSolutions in a research report on Friday, September 13th. Finally, StockNews.com downgraded Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Saturday.

Emergent BioSolutions Trading Up 11.9 %

NYSE EBS traded up $0.98 on Monday, hitting $9.25. 1,663,194 shares of the company were exchanged, compared to its average volume of 3,108,493. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10. The firm has a market capitalization of $501.20 million, a P/E ratio of -2.26 and a beta of 1.59. The company's 50 day moving average price is $9.19 and its 200-day moving average price is $8.91.

Institutional Trading of Emergent BioSolutions

Several large investors have recently added to or reduced their stakes in the business. SeaCrest Wealth Management LLC grew its holdings in Emergent BioSolutions by 3.2% during the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company's stock valued at $991,000 after purchasing an additional 3,705 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Emergent BioSolutions in the 2nd quarter valued at $41,000. Verus Capital Partners LLC bought a new position in Emergent BioSolutions in the 2nd quarter worth $68,000. Stifel Financial Corp acquired a new position in Emergent BioSolutions during the 3rd quarter worth $96,000. Finally, FORA Capital LLC bought a new stake in Emergent BioSolutions during the third quarter valued at about $103,000. 78.40% of the stock is owned by institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.